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OBJECTIVE: This paper presents the results of an eco-
nomic evaluation comparing Letrozole, a third generation
aromatase inhibitor, and Tamoxifen as ﬁrst-line hormonal
therapies in postmenopausal women diagnosed with
advanced breast cancer in Germany. METHODS: A
recently published economic model was applied in which
data from a recent RCT comparing Letrozole and 
Tamoxifen were employed supplemented with data from
the literature and expert panels German cost data was
introduced. These data were synthesised within a Markov
process that described relevant events along patients path-
ways from diagnosis to death and analysed using decision
modelling software. The evaluation perspective was that
of the German healthcare system. The time horizon
covered the full lifetime of the patients. Discount rates of
5% for resources and 5% for life years were applied to
all analyses due to missing guidance in Germany like UK
Treasury guidelines. A probabilistic sensitivity analysis
was undertaken in line with the original model.
RESULTS: The mean baseline results derived from the
stochastic analysis of the model for both Letrozole and
Tamoxifen show that patients receiving Letrozole gain
additional 0.30 life years, whilst the difference in lifetime
treatment costs is €802.45. The mean cost of gaining an
additional life year from the use of Letrozole was esti-
mated as €2,673.50. Limits of the “credible interval” for
the incremental cost-effectiveness ratio (ICER) were at the
5th percentile “Letrozole dominating”, whilst the 95th
percentile reveals an ICER of €7,394.75 per life year
gained. CONCLUSION: The model extrapolated the
available clinical trial data using published data, expert
opinion and German cost data to estimate the cost per
life year saved in Germany compared to the standard ﬁrst-
line therapy of Tamoxifen. The mean results indicate that
in Germany Letrozole is a cost-effective alternative ﬁrst-
line therapy compared to Tamoxifen.
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OBJECTIVE: Most newly diagnosed non-small cell lung
cancers are too advanced at detection to be surgically
amenable. Recently it was found that poly-chemotherapy
may improve these patients’ survival signiﬁcantly, but 
no single regimen has yet been deﬁnitely determined as
preferable. This study reports an economic evaluation of
cisplatin-paclitaxel, considered the standard therapy in
the trial, compared to cisplatin-gemcitabine and pacli-
taxel-gemcitabine respectively. METHODS: Data on the
use of medical resources were collected in a phase III clin-
ical trial comparing the regimens. Costs are determined
from the viewpoint of the Dutch health insurance system.
The principal outcome measure for the economic evalu-
ation is mean survival time estimated by a restricted
means analysis with restriction time point determined by
statistical criteria. Costs are corrected for censoring using
Lin’s subinterval method, and the impact of uncertainty
is examined by applying bootstrap techniques. The analy-
sis focuses on estimation of the joint density of cost and
outcome differences, quantiﬁcation of the uncertainty
surrounding base case point estimates and derivation 
of cost-effectiveness acceptability curves. RESULTS: Base
case estimates of costs and outcomes are virtually identi-
cal for the cisplatin-paclitaxel and cisplatin-gemcitabin
groups. Average total cost (ATC) per patient in each arm
is around €17,000, but the cost composition differs 
considerably. Higher cytotoxics costs in the cisplatin-
paclitaxel group are balanced by higher costs of 
hospitalization and blood transfusions in the cisplatin-
gemcitabin group due to a higher incidence of severe
hematological toxicities and emesis. Gemcitabin-
paclitaxel leads to considerably higher ATC of €20,900
per patient and a non-signiﬁcant reduction of survival
time compared to cisplatin-paclitaxel. CONCLUSION:
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